AIM ImmunoTech Inc. (AIM) News
Track canonical SquawkNews coverage tagged to AIM, AIM ImmunoTech Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 21 indexed stories across 14 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
Copernico Sim Approves Capital Increase For 4Timing Deal
Copernico SIM SpA MIL:COP
NEWS | Sep 25, 2026, 01:13 PM UTC
M
AIM ImmunoTech CEO letter outlines Ampligen role after daraxonrasib approval
AIM ImmunoTech said Ampligen’s differentiated mechanism may support a pancreatic-cancer role following FDA approval of daraxonrasib, citing retrospective survival data and targeting DURIPANC Phase 2 readouts in 2027.
EQUITY | Sep 22, 2026, 01:01 PM UTC
L
AIM ImmunoTech Converts ~$400,000 of Debt Into 1.75M Shares With Streeterville Capital
AIM ImmunoTech completed two debt-for-equity exchanges with Streeterville Capital on September 8 and 9, 2026, converting approximately $400,000 of principal from a November 18, 2025 promissory note into 1,749,434 shares
EQUITY | Sep 14, 2026, 08:47 PM UTC
M
AIM ImmunoTech converts $450,000 note into 1,921,441 shares
AIM ImmunoTech executed two debt-for-equity exchanges with Streeterville Capital on September 3 and 4, 2026, tied to its November 18, 2025 promissory note. Around $450,000 of principal was converted into 1,921,441 shares
MNA | Sep 10, 2026, 08:44 PM UTC
L
Aimia Inc publishes Schedule One update for AIM
The company filed an RNS announcement titled "Schedule One Update" on 10 September 2026.
EQUITY | Sep 10, 2026, 03:00 PM UTC
L
AIM - AIM ImmunoTech Highlights Scientific Rationale, Supportive Data and Continued Advancement of Ampligen® in Pancreatic Cancer in New CEO
AIM - AIM ImmunoTech Highlights Scientific Rationale, Supportive Data and Continued Advancement of Ampligen® in Pancreatic Cancer in New CEO Corner Video
EQUITY | Sep 09, 2026, 01:03 PM UTC
L
AIM Aimia Inc issues Schedule One update via RNS
Aimia Inc has published a Schedule One update via an RNS announcement (RNS Number: 9078T), as provided by the London Stock Exchange news service.
EQUITY | Sep 08, 2026, 03:00 PM UTC
L
AI-Media Puts Multilingual AI at the Heart of the Broadcast Workflow at IBC2026
New LEXI Encoders, expanded LEXI Suite, LEXI Direct and partner integrations bring scalable AI-powered language capabilities into broadcast workflowsAI-Media Attending IBC 2026 - Booth 5.C34See how LEXI AD uses AI to cre
EQUITY | Sep 03, 2026, 10:07 AM UTC
L
Advance Information Marketing Malaysia 2026 4Q revenue, pre-tax loss
Advance Information Marketing Malaysia reported 4Q results for the quarter ended Jun 30 in MYR. 2026 revenue was 763,000 MYR versus 1,734,000 MYR in 2025, with pre-tax profit of -2,538,000 MYR.
EARNINGS | Sep 03, 2026, 09:06 AM UTC
L
AIM ImmunoTech expands Ampligen long COVID patent coverage through 2041
AIM ImmunoTech expands its Ampligen® global patent estate for long COVID protection in Europe and the United Kingdom through 2041.
EQUITY | Sep 02, 2026, 12:43 PM UTC
L
Morgans raises AIM price target for Ai-Media Technologies by 18%
Morgans raised its price target on Ai-Media Technologies (AIM) by 18% to A$0.26 per share.
EQUITY | Aug 27, 2026, 11:37 PM UTC
L
AIM - AIM ImmunoTech Participates in the Virtual Investor ‘Why Now’ On-Demand Conference
AIM - AIM ImmunoTech Participates in the Virtual Investor ‘Why Now’ On-Demand Conference
EQUITY | Aug 27, 2026, 01:08 PM UTC
L
JTC Team Releases Virtual Investor "Why Now" On-Demand Conference Featuring Nine Public Company CEOs
JTC Team Releases Virtual Investor "Why Now" On-Demand Conference Featuring Nine Public Company CEOs
EQUITY | Aug 27, 2026, 01:01 PM UTC
L
Ai-Media Technologies reports FY adjusted EBITDA of A$2.1M
Ai-Media Technologies posted FY adjusted EBITDA of A$2.1 million.
EQUITY | Aug 27, 2026, 01:36 AM UTC
H
AIM - AIM ImmunoTech CEO Highlights Biodefense and Military Force Protection in Newly Published ‘Breaking Defense’ Article - Click For Relea
AIM - AIM ImmunoTech CEO Highlights Biodefense and Military Force Protection in Newly Published ‘Breaking Defense’ Article
EQUITY | Aug 12, 2026, 12:44 PM UTC
H
AIM ImmunoTech Ahead on DURIPANC Trial
AIM ImmunoTech reaches critical clinical inflection point
EQUITY | Aug 03, 2026, 12:33 PM UTC
L
Great Western Mining Corporation PLC Announces Exercise of Warrants and Issue of Equity
DUBLIN, IRELAND / / July 3, 2026 / Great Western Mining Corporation PLC (AIM:GWMO)(ESM:8GW) announces that it ha
EQUITY | Jul 03, 2026, 11:30 AM UTC
L
Update on Intention to Move from AIM to Main Market
Reykjavík, July 03, 2026 (GLOBE NEWSWIRE) -- THIS ANNOUNCEMENT IS MADE FOR INFORMATION
EQUITY | Jul 03, 2026, 06:00 AM UTC
H
RTX CORP - RAYTHEON INCREASES AIM-9X MISSILE PRODUCTION CAPACITY TO 2500 PER YEAR
RTX CORP - RAYTHEON INCREASES AIM-9X MISSILE PRODUCTION CAPACITY TO 2500 PER YEAR
GEOPOLITICS | Jun 26, 2026, 12:01 PM UTC
M
AIM Outlines Milestones
AIM ImmunoTech outlines upcoming milestones, including DURIPANC primary endpoint analysis expected in December 2026
EARNINGS | Jun 24, 2026, 12:36 PM UTC